VCNX Vaccinex, Inc. Stock Quote

VCNX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	1.70%	Shs Outstand	38.76M	Perf Week	3.51%
Market Cap	48.67M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	37.52M	Perf Month	-3.28%
Income	-22.40M	PEG	-	EPS next Q	-	Inst Own	44.20%	Short Float	1.44%	Perf Quarter	-11.28%
Sales	0.90M	P/S	54.08	EPS this Y	49.50%	Inst Trans	76.20%	Short Ratio	4.39	Perf Half Y	-26.71%
Book/sh	0.42	P/B	2.81	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-49.57%
Cash/sh	0.41	P/C	2.90	EPS next 5Y	-	ROE	-	52W Range	0.90 - 3.28	Perf YTD	13.46%
Dividend	-	P/FCF	-	EPS past 5Y	19.40%	ROI	-280.70%	52W High	-64.02%	Beta	1.10
Dividend %	-	Quick Ratio	10.00	Sales past 5Y	23.30%	Gross Margin	-	52W Low	31.11%	ATR	0.09
Employees	39	Current Ratio	10.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.60	Volatility	9.42% 8.72%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.40	Prev Close	1.16
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	122.84K	Price	1.18
Recom	1.00	SMA20	-3.16%	SMA50	-7.73%	SMA200	-26.80%	Volume	49,127	Change	1.72%

Sep-23-20

Downgrade

BTIG Research

Buy → Neutral

Sep-04-18

Initiated

Ladenburg Thalmann

Buy

$22

May-25-22 08:00AM	Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET GlobeNewswire
May-16-22 08:15AM	Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update GlobeNewswire
Apr-25-22 08:00AM	Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery GlobeNewswire
Mar-31-22 09:15AM	Vaccinex Reports 2021 Financial Results and Provides Corporate Update GlobeNewswire
Mar-09-22 09:00AM	Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer GlobeNewswire +19.27%
Feb-24-22 08:00AM	Vaccinex, Inc. to Present at CHDIs 17th Annual HD Therapeutics Conference Meeting GlobeNewswire
Feb-11-22 11:24AM	With stock up 25%, Insiders of Vaccinex, Inc. (NASDAQ:VCNX) must be wishing they had bought more last year Simply Wall St. -8.76%
Jan-28-22 07:57AM	Vaccinex's CEO, Chairman To Inject $4M To Fund The Lead Program Benzinga +23.50%
Jan-27-22 04:15PM	Vaccinex Announces $6.6 Million Private Placement GlobeNewswire -17.57%
Jan-26-22 11:18AM	Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck Cancer Benzinga +8.82%
08:00AM	Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer GlobeNewswire
Jan-04-22 08:00AM	Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis GlobeNewswire
Nov-10-21 08:00AM	Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting GlobeNewswire
Nov-09-21 08:00AM	Vaccinex, Inc. to Present at the Clinical Trials on Alzheimers Disease (CTAD) Meeting GlobeNewswire
Nov-08-21 08:15AM	Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-21 08:00AM	Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference GlobeNewswire
Nov-01-21 08:00AM	Vaccinex to Present at the Virtual Huntingtons Study Group Meeting on November 4-6, 2021 GlobeNewswire
Sep-17-21 08:00AM	Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit GlobeNewswire
Sep-15-21 08:00AM	Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntingtons Disease Network Meeting GlobeNewswire
Aug-16-21 08:15AM	Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-21-21 07:45AM	A Look At Vaccinex's (NASDAQ:VCNX) Share Price Returns Simply Wall St.
Jun-30-21 08:00AM	Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease GlobeNewswire
Jun-08-21 07:57AM	Vaccinex Initiates Pepinemab Trials for Alzheimer's, Head & Neck Cancer Benzinga
07:00AM	Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimers Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) GlobeNewswire
May-19-21 08:00AM	Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference GlobeNewswire
May-17-21 08:15AM	Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Apr-21-21 08:00AM	Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research GlobeNewswire +7.33%
Mar-16-21 08:05AM	Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Mar-11-21 08:00AM	Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference GlobeNewswire +7.47%
Feb-23-21 07:25AM	The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga -21.92%
Feb-22-21 08:30AM	Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology GlobeNewswire
Feb-19-21 12:20PM	Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers MarketWatch +70.03%
10:36AM	VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring InvestorPlace
07:30AM	Vaccinex Spikes on Deals with Two Pharma Companies TheStreet.com
Jan-07-21 08:19AM	Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech Zacks +6.19%
Jan-06-21 08:43AM	Bet on Rising P/E With These 5 Top-Ranked Stocks Zacks
Jan-05-21 08:00AM	Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event GlobeNewswire
Nov-13-20 08:05AM	Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Oct-29-20 11:15AM	CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference GlobeNewswire
Oct-26-20 07:55AM	Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable GlobeNewswire +6.38%
Oct-12-20 08:53AM	Implied Volatility Surging for Vaccinex (VCNX) Stock Options Zacks -5.86%
Sep-23-20 10:34AM	Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More Zacks -19.83%
Sep-22-20 08:40AM	Vaccinex's stock falls after investigational drug fails Huntington's disease study MarketWatch -57.59%
07:30AM	Top-Line Results of Phase 2 SIGNAL Study in Huntingtons Disease Support Potential for Cognitive Benefit of Pepinemab GlobeNewswire
Sep-17-20 08:00AM	Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma GlobeNewswire +12.10%
Aug-27-20 08:00AM	Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer GlobeNewswire
Aug-14-20 09:45AM	Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates Zacks +11.84%
08:30AM	Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-20 12:30PM	Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-16-20 11:30AM	3 Stocks Flashing Signs of Strong Insider Buying TipRanks +9.69%
Jul-07-20 08:37AM	Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1% Zacks
07:55AM	Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntingtons Disease GlobeNewswire
Jun-09-20 08:00AM	Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series GlobeNewswire
May-14-20 10:05AM	Vaccinex Inc (VCNX) Reports Q1 Loss, Lags Revenue Estimates Zacks +8.22%
08:45AM	Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
May-13-20 05:02PM	Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting GlobeNewswire -5.19%
12:30PM	Vaccinex Inc (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-27-20 07:45AM	Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting GlobeNewswire +7.47%
Apr-07-20 07:55AM	Vaccinex Delivers Virtual Presentation at the Advances in Alzheimers and Parkinsons Therapies AAT-AD/PD Focus Meeting 2020 GlobeNewswire
Mar-31-20 07:55AM	Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs GlobeNewswire
Mar-09-20 07:46AM	Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-06-20 07:31AM	Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Dec-10-19 08:02AM	Vaccinex Announces $3 Million Award from the Alzheimers Drug Discovery Foundation GlobeNewswire
Dec-09-19 07:55AM	Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimers Disease GlobeNewswire
Nov-25-19 07:18PM	Is Vaccinex, Inc. (VCNX) Burning These Hedging Funds ? Insider Monkey +5.28%
Nov-14-19 07:55AM	Vaccinex Announces Award Notice from the Alzheimers Association 2020 Part the Cloud Program GlobeNewswire
Nov-12-19 08:00AM	Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +12.03%
Nov-09-19 08:02AM	Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire
Oct-31-19 09:14AM	Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board GlobeNewswire
Sep-27-19 06:05AM	Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France GlobeNewswire -5.74%
Sep-24-19 08:05AM	Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire +10.29%
Sep-06-19 10:45AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX GlobeNewswire
Aug-14-19 12:18PM	Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study Zacks
08:30AM	Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-13-19 08:05AM	Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer GlobeNewswire
Aug-12-19 05:49PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaccinex, Inc.- VCNX GlobeNewswire
Aug-02-19 01:41PM	Insiders Roundup: Bezos Sells Amazon GuruFocus.com
Aug-01-19 09:15AM	Vaccinex Inc (VCNX) President and CEO Maurice Zauderer Bought $750,002 of Shares GuruFocus.com
Jul-31-19 07:30AM	Vaccinex Announces $13.8 Million Private Placement GlobeNewswire
Jun-03-19 08:00AM	Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting GlobeNewswire
May-15-19 08:10AM	Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting GlobeNewswire
08:05AM	Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-09-19 08:30AM	Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire
Apr-01-19 08:00AM	Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire
Mar-13-19 08:30AM	Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019 GlobeNewswire
07:16AM	Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-06-19 08:30AM	Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Jan-17-19 08:30AM	Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntingtons Disease (the SIGNAL Trial) at Cambridge Healthtech Institutes 18th Annual PepTalk GlobeNewswire
Jan-16-19 08:30AM	Vaccinex, Inc. Announces Completion of Enrollment for Its SIGNAL Huntingtons Disease Trial GlobeNewswire
Dec-12-18 12:18PM	Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)? Simply Wall St.
08:30AM	Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research GlobeNewswire
Nov-27-18 07:30AM	Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event ACCESSWIRE
Nov-15-18 08:30AM	Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Nov-13-18 07:58AM	Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-12-18 08:30AM	Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntingtons Disease at the Huntington Study Groups 2018 Annual Meeting GlobeNewswire
Nov-06-18 08:30AM	Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntingtons Disease GlobeNewswire
Oct-23-18 08:30AM	Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018 GlobeNewswire
Oct-02-18 08:30AM	Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-27-18 08:30AM	Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-25-18 08:30AM	Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Van Strydonck, Gerald E.	Director	Feb 23	Buy	1.32	20,000	26,360	20,000	Feb 24 04:37 PM
Frieberg Jacob B.	Director	Jan 27	Buy	1.11	90,090	100,000	94,510	Jan 31 04:26 PM
FRIEDBERG ALBERT	Director	Jan 27	Buy	1.11	3,603,602	3,999,998	11,580,436	Jan 31 04:24 PM
Zauderer Maurice	President and CEO	Jan 27	Buy	1.11	1,801,801	1,999,999	2,899,554	Jan 31 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience